We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1326
Option Care Health
OPCH
$4.67B
| $518K | ﹤0.01% |
15,942
-1,089
| -6% | -$35.2K |
2021 Q3
15 quarters
|
|
1327
Genworth Financial
GNW
$3.37B
| $515K | ﹤0.01% |
66,225
+195
| +0.3% | +$1.36K |
2022 Q3
11 quarters
|
|
1328
Public Service Enterprise Group
PEG
$35B
| $512K | ﹤0.01% |
6,081
-325
| -5% | -$26.2K |
2013 Q2
48 quarters
|
|
1329
The GEO Group
GEO
$3.89B
| $511K | ﹤0.01% |
21,349
-799
| -4% | -$21.8K |
2025 Q1
1 quarter
|
|
1330
Vontier
VNT
$4.45B
| $509K | ﹤0.01% |
13,807
-346,096
| -96% | -$11.8M |
2020 Q4
18 quarters
|
|
1331
Crown Castle
CCI
$34.3B
| $509K | ﹤0.01% |
4,955
+261
| +6% | +$26.4K |
2013 Q2
48 quarters
|
|
1332
DELISTED
Hologic
HOLX
| $504K | ﹤0.01% |
7,730
-418
| -5% | -$25.1K |
2024 Q2
4 quarters
|
|
1333
Beam Therapeutics
BEAM
$2.51B
| $496K | ﹤0.01% |
29,165
-964
| -3% | -$16.8K |
2024 Q2
4 quarters
|
|
1334
Conagra Brands
CAG
$6.83B
| $495K | ﹤0.01% |
24,206
+2,798
| +13% | +$65.6K |
2021 Q4
14 quarters
|
|
1335
Envista
NVST
$3.76B
| $495K | ﹤0.01% |
25,350
-1,150
| -4% | -$20K |
2020 Q2
20 quarters
|
|
1336
Home BancShares
HOMB
$5.72B
| $488K | ﹤0.01% |
17,143
-364
| -2% | -$10.1K |
2015 Q4
38 quarters
|
|
1337
FirstCash
FCFS
$9.41B
| $487K | ﹤0.01% |
3,603
-84
| -2% | -$10.7K |
2019 Q3
23 quarters
|
|
1338
HF Sinclair
DINO
$22.1B
| $483K | ﹤0.01% |
11,762
-3,382
| -22% | -$116K |
2021 Q2
16 quarters
|
|
1339
United Bankshares
UBSI
$6.33B
| $482K | ﹤0.01% |
13,230
-288
| -2% | -$10.1K |
2017 Q2
32 quarters
|
|
1340
Shift4
FOUR
$3.1B
| $482K | ﹤0.01% |
4,859
-144
| -3% | -$12.6K |
2024 Q4
2 quarters
|
|
1341
Corcept Therapeutics
CORT
$12.2B
| $480K | ﹤0.01% |
6,537
-6,335
| -49% | -$459K |
2013 Q2
48 quarters
|
|
1342
Blackstone
BX
$87.3B
| $475K | ﹤0.01% |
3,175
-42
| -1% | -$5.77K |
2022 Q4
10 quarters
|
|
1343
Alphatec Holdings
ATEC
$1.68B
| $474K | ﹤0.01% |
+42,723
| New | +$491K |
2025 Q2
0 quarters
|
|
1344
VeriSign
VRSN
$27.2B
| $474K | ﹤0.01% |
1,642
+849
| +107% | +$230K |
2024 Q3
3 quarters
|
|
1345
Gold Fields
GFI
$32.8B
| $474K | ﹤0.01% |
20,027
| – | – |
2022 Q1
13 quarters
|
|
1346
Lumentum
LITE
$77B
| $474K | ﹤0.01% |
4,985
+338
| +7% | +$24K |
2016 Q4
34 quarters
|
|
1347
Gentex
GNTX
$4.46B
| $471K | ﹤0.01% |
21,414
-1,598
| -7% | -$34.9K |
2013 Q2
48 quarters
|
|
1348
Boise Cascade
BCC
$2.63B
| $467K | ﹤0.01% |
5,384
+67
| +1% | +$6.07K |
2016 Q3
35 quarters
|
|
1349
Bank OZK
OZK
$5.02B
| $464K | ﹤0.01% |
9,863
-127
| -1% | -$5.56K |
2014 Q4
42 quarters
|
|
1350
AutoNation
AN
$5.3B
| $461K | ﹤0.01% |
2,323
-118
| -5% | -$21.3K |
2017 Q3
31 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.